EMA states that reduction in animal testing will be gradual. The first qualification opinion for a NAM used in toxicity ...
Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...
Lilly acquires Centessa for $6.3B, gaining an orexin receptor agonist pipeline targeting narcolepsy and other sleep-wake ...
Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...
The 2023 revision of Annex 1 of the European Union’s good manufacturing practice (GMP) guidelines 1 represents a fundamental shift in expectations for sterile manufacturing. Reg ...
During its March 2026 meeting, the agency’s Committee for Medicinal Products for Human Use approved treatments for Bacillus ...
Using patent intelligence data from the FounderNest platform, alongside funding, partnership, and deployment signals across ...
EMA approved Johnson & Johnson’s daratumumab SC for self-administration, Europe’s first oncology injectable to offer this ...
Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system ...
The FDA has approved a high-dose regimen of Biogen’s nusinersen (SPINRAZA) for the treatment of spinal muscular atrophy. 1 ...
Michelle Dennis, QC Microbiology Application Specialist with MilliporeSigma and member of the PDA Week 2026 planning ...
Ryan Murray, ValSource, breaks down far UVC technology, holistic contamination control strategies, and environmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results